Changes in Cardiovascular Risk Factors and Health Care Expenditures Among Patients Prescribed Semaglutide.

ABSTRACT:

Importance

Semaglutide, a glucagon-like peptide-1 receptor agonist, has demonstrated substantial weight reduction and cardiovascular benefits in clinical trials. However, its association with clinical outcomes and health care expenditures remains underexplored.

Objective

To evaluate changes in cardiovascular risk factors and health care expenditures among patients prescribed semaglutide across multicenter cohorts.

Design, setting, and participants

This retrospective cohort study included 23 522 adults (≥18 years) who received an initial semaglutide prescription between January 1, 2018, and January 1, 2025, at Sentara Healthcare and between January 1, 2018, and May 1, 2025, at Yale New Haven Health System.

Exposure

The first prescription of semaglutide identifie

SUBMITTER: Lu Y 

PROVIDER: S-EPMC12334959 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature